Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Calendar
  • Grants
  • About Akademiliv
Emma Aneheim och Sture Lindgren arbetar vid den prottyp de utvecklar för att automatisera

Emma Aneheim receives Swedish Cancer Society fellowship

3 June, 2019

GRANTS. With her colleagues, she is working on developing a treatment based on targeted radiation therapy, which may improve the chances of preventing relapses in ovarian cancer. Emma Aneheim, a researcher at the Department of Radiation Physics, has now received a fellowship through the Swedish Cancer Society’s Fellowship in Ovarian Cancer Research.

Ovarian cancer is usually treated with surgery, followed by anti-cancer drugs. Because the disease has often spread into the abdominal cavity by the time it is discovered, it is difficult to completely eradicate the cancer cells, and many patients suffer a relapse. The project in which Emma Aneheim is participating involves connecting the alpha-radiating isotope astatine-211 with antibodies.

Emma Aneheim

“We believe the research potentially can lead to a local treatment that is applied ‘up front’ after surgery and chemotherapy, making it possible to cure more patients with otherwise poor prognoses,” says Aneheim, whose fellowship is now being funded for three years, thanks to the Swedish Cancer Society grant.

The research team is ready to start implementing a phase I study, in which a small group of ovarian cancer patients will receive antibodies with astatine-211, primarily to investigate whether the treatment is safe. Part of Aneheim’s work involves developing clinical protocols for chemical production of the radioactive antibody-drug conjugate that patients will receive in future studies.

“The clinical protocol for the phase I study will include all radiochemical production steps, all material and chemicals will be validated, the radioactive pharmaceutical production system will be approved, and the astatine-211-labeled antibody will need to be clinically validated.”

So far there is only this prototype of the machine that automates the linking of astat-211 to the antibodies.

The team is also preparing for the future phase II and phase III studies. These most likely will be implemented in collaboration among several university hospitals, which will require automated production of the radioactive pharmaceutical.

“Our prototype system needs further development purely in technical terms, and it also needs to be transferred to a CE-marked clinical system. In addition, the radioactive pharmaceutical product from the clinical system needs to be validated.”

The chemical process by which astatine-211 is extracted and connected with the antibodies is difficult and requires specialized knowledge, but there is a method for automating production that Sture Lindgren and Emma Aneheim have developed together. So far the machine is a prototype, and part of Aneheim’s job will be validating the prototype clinically so they can develop the technology and prepare for more large-scale studies. At my visit to the laboratory, the machine was being prepared for the next shipment of astatine-211 from Rigshospitalet in Copenhagen. Production of the isotope requires a more advanced cyclotron than the one currently at Sahlgrenska University Hospital.

Astatine, the rarest element in the world, exists only in radioactive form with a short half-life. Among cancer researchers, there is a broad interest in the astatine-211 isotope. Unlike iodine-131, which currently is widely used in health care, astatine-211 radiates alpha particles that have a very limited range in tissues so it can be used for targeted radiation treatment. Efforts to develop a new treatment for ovarian cancer based on antibodies and astatine-211 have been under way for many years in Gothenburg, and other early clinical trials also have been carried out.

“A phase I study has investigated dose escalation and toxicity. The results did not point to any problems with the phase I study we are going to conduct. We have everything in place for it to go well,” says Aneheim.

Emma Aneheim defended her thesis on nuclear chemistry at Chalmers University of Technology, where she became interested in working on medical implementations in connection with a guest lecture Lindgren presented at Chalmers. After her dissertation she switched tracks and became a postdoctoral researcher at the Department of Radiation Physics.

“The step from nuclear chemistry is not as large as it might seem. For me the main difference is that the half-lives of the materials I work with now are so much shorter. I have had to learn to work in completely different ways because the isotopes disintegrate so quickly,” says Aneheim.

TEXT AND PHOTO: ELIN LINDSTRÖM CLAESSEN

 

By: Elin Lindström
Tagged With: Bidrag och stipendier, Bidrag och stipendier

Add your own events in the Akademiliv Calendar

No newsletter during the sports holiday – Wednesday, February 15

Information from Sahlgrenska Academy Research Support Office

[UPDATED JAN 24]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated approximately four times per semester.

’20 minutes for researchers’ is back – see full spring program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

We are building at Medicinareberget

You will now find comprehensive information on construction projects that affect the Sahlgrenska Academy in the Staff Portal.

Lunch menus

Café Anatomen
Menu not available on website.

Café Annedal
Menu not available on website.

Lunchen.nu

Lustgården på Änggårdsbacken
Take away for external guests between 11.00-12.30 weekdays.

Lyktan

Mersmak Mölndal

Mersmak Sahlgrenska

Mersmak Östra

Salt & Syra

More news

Nominations for Honorary Doctors 2023 is open

2 February, 2023

HONORARY DOCTOR. All staff at Sahlgrenska Academy may nominate honorary doctorates. The appointments are evidence of the faculty’s appreciation, a …  

Depression and low quality of life 30 years after chemical attack

27 January, 2023

NEW STUDY. Mustard gas harms the vision, skin and breathing. Three decades on, however, the predominant effect is mental ill-health. At a time …  

Testing a immunological drug as a new treatment for early type 1 diabetes

26 January, 2023

CLINICAL STUDY. A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were …  

Emma Eckernäs: GU now surveying doctoral students’ work environment too

25 January, 2023

COLUMN. For the first time, the work environment survey (ARK) at the University of Gothenburg (GU) now contains a sub-survey aimed specifically …  

Nominate for the award “PhD Thesis of the Year”

24 January, 2023

AWARD. Do you know of a really good thesis that was defended last year? Until February 7, you can nominate for the Sahlgrenska Academy's PhD …  

New legislation for clinical trials of medicinal products

24 January, 2023

RESEARCH RESOURCES. New EU legislation for clinical trials of medicinal products will be phased in over the coming years. All new applications …  

Joining forces for research on asthma, allergy, and airways

24 January, 2023

RESEARCH CONDITIONS. "Breathe Sweden", a digital platform for researchers who collect studies on diseases and disorders of the respiratory tract, …  

Fewer surgically treated ankle fractures with a clear-cut treatment routine

24 January, 2023

DOCTORAL THESIS. It has been shown that the percentage of ankle fractures that undergo surgery could be substantially reduced, from more than 30 …  

In memory of Bo Lundbäck

23 January, 2023

COMMEMORATIVE REMARKS: On December 6, Professor Bo Lundbäck passed away at the age of 74 after a period of illness. He was a senior professor in …  

Hope of more donor hearts suitable for transplantation

23 January, 2023

MULTICENTER STUDY. Improved Heart is the first prospective multicenter study in the world where evaluation of organ donors’ cardiac function is g …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen